CD274 and non-small cell lung carcinoma: The benefit of atezolizumab in PD-L1 positive patients was also observed in those with stage II-IIIA NSCLC in the adjuvant setting (4) and those with metastatic NSCLC receiving first- or second-line treatment (36, 37).